Dermatoscopy Course

Symposium 2
Management of toxicities of targeted therapies

Symposium 5
Prognostic and predictive markers in melanoma

Authorization has not been given for online viewing of this talk:

• Dirk Schadendorf -- Where do we stand with tissue based markers?

Satellite Symposium 1

Symposium 8
Management of toxicities of immunocheckpoint inhibitors

Symposium 11
Management of actinic keratosis and field cancerization

Authorization has not been given for online viewing of this talk:

• Nicole Kelleners-Smeets -- Why treat Actinic Keratosis

Satellite Symposium 4

Symposium 14
Surgical management of non-melanoma skin cancer

Authorization has not been given for online viewing of this talk:

• Cristina Magnoni -- NMSC surgery of the face - My favourite techniques

Symposium 16
Challenging cases in dermoscopy

Satellite Symposium 8

Symposium 21
When should we stop systemic treatment in skin cancer and when to offer supportive care?

Surgery Course

Authorization has not been given for online viewing of this talks:

• Nicole Kelleners-Smeets -- Biopsy and shaving procedures in skin cancer - when, why and how?
• Myrto Trakatelli -- Basics of flaps and grafts

Symposium 3
Epidemiology and prevention of skin cancer

Symposium 6
Management of melanocytic nevi

Satellite Symposium 2

Symposium 9
Management of cutaneous lymphoma

Symposium 12
Skin cancer management in particular clinical settings

Satellite Symposium 5

Symposium 17
Management of other malignant cutaneous tumors

EuMelaReg Meeting (The Europen Melanoma Registry)

Authorization has not been given for online viewing of this talk:

• Dirk Schadendorf -- Current scientific projects

Symposium 22
Occupational skin cancer

Authorization has not been given for online viewing of this talk:

• Stephan Brandenburg -- Skin cancer: 2nd most frequently recognized occupational disease in Germany. The perspective of a social accident insurance on a rapidly increasing workers’ health issue

SCOPE Symposium (Skin Care in Organ Transplant Patients)
(Skin Care in Organ Transplant Patients)

Authorization has not been given for online viewing of this talks:

• Alessandra Handisurya -- The role of papillomavirus infection in skin carcinogenesis
• Deniz Seckin -- Main issues of cutaneous lymphoma in organ transplant recipients

Free communications 1
Melanoma diagnosis & treatment

Satellite Symposium 6

Free communications 2
Non-Melanoma Skin Cancer diagnosis & treatment I (BCC & SCC)

Free communications 3
Basic research, genetics and epidemiology of skin cancer

Free communications 4
Non-melanoma skin cancer diagnosis & treatment II (lymphoma, merkel, sarcoma, etc.)

Expanding Horizons in the Treatment of NMSC: the Role of Immunotherapy
Room 1 (Main)

Welcome and opening remarks
Professor Ulrike Leiter-Stöppke, Tübingen, Germany

A standard of care in advanced cutaneous squamous cell carcinoma: the application of immunotherapy
Professor Ulrike Leiter-Stöppke, Tübingen, Germany

Defining high-risk cutaneous squamous cell carcinoma: pathway to improved clinical practice
Professor Vishal Patel, Washington, DC, USA

Breaking new ground in the treatment of advanced basal cell carcinoma
Professor Maria Concetta Fargnoli, L'Aquila AQ, Italy

Ask the faculty and concluding remarks
All Faculty

DecisionDx: Use of gene expression profiles to personalize management of skin cancer patients
Room 2
Peter A. Prieto, MD, MPH, CMQ, FACS, FSSO (Rochester, USA)

Are we achieving optimal outcomes in melanoma?
Room 1 (Main)

Chair: Axel Hauschild (Germany)

Welcome and introduction
Axel Hauschild
What are the current achievements in the treatments of patients with resected high-risk melanoma?
Axel Hauschild

What are the achievements and remaining unmet needs in the advanced melanoma setting?
Olivier Michielin

7 years of long-term benefit of immunotherapy
Caroline Robert

Panel discussion and Q&A
Faculty

Closing remarks
Axel Hauschild

A global approach in the management of sun-damaged skin and cutaneous cancer
Room 1 (Main)

Welcome & Introduction
Prof. Josep Malvehy (Barcelona, Spain) / Chair

Photoprotection in digital area: blue light and Triasorb
Prof. Eggert Stockfleth (Bochum, Germany)

Treatments for AK and the effect on occurrence of SCC
Prof. Klara Mosterd (Maastricht, The Netherlands)

Number of lesions in a FC: consequences on the assessment of efficacy and local tolerability of field directed treatments
Prof. Eggert Stockfleth (Bochum, Germany)

Management of early-stage melanoma: the Oncologist perspective
Prof. Mario Mandala (Perugia, Italy)

Skin photosensitivity reactions in cancer patients: clinical pearls
Dr. Ander Mayor (Madrid, Spain)

Q&A
All participants

Conclusion
Prof. Josep Malvehy (Barcelona, Spain)/Chair

Clinical Decision Making in Melanoma: Focus on Treatment Sequencing
Room 2

Welcome and introduction
James Larkin (UK), PhD, FRCP, FMedSci

Clinical scenario 1 - treatment selection for a patient with stage 3 BRAF-mutant melanoma

Case presentation
Céleste Lebbé (France), MD, PhD, Prof

Treatment plan, rationale, and outcomes
James Larkin (UK), PhD, FRCP, FMedSci

Live case review, debate, and audience questions
All faculty, moderated by Eva Muñoz Couselo (Spain), MD, PhD

Clinical scenario 2 - treatment of a patient with BRAF-mutant metastatic melanoma

Case presentation
James Larkin (UK), PhD, FRCP, FMedSci

Treatment plan, rationale, and outcomes
Céleste Lebbé (France), MD, PhD, Prof

Live case review, debate, and audience questions
All faculty, moderated by Eva Muñoz Couselo (Spain), MD, PhD

Summary and close
Céleste Lebbé (France), MD, PhD, Prof

Sonidegib’s Positioning in the Evolving laBCC Treatment Landscape
Room 3

Intro & Welcome
Prof. David Moreno Ramírez. Seville, Spain

French Sonidegib Real Life Data
Prof. Nicole Basset-Seguin. Paris, France

Established Positioning of Hedgehog Inhibitors for the Treatment of laBCC
Prof. Ketty Peris. Rome, Italy

Discussion
All Faculty

Closure
Prof. David Moreno Ramírez. Seville, Spain

Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy
Room 4

Faculty: Prof. Axel Hauschild, MD (Chair)
David M. Miller, MD, PhD, FAAD, Vishal Anil Patel, MD, FAAD, FACMS

Welcome and introduction
Prof. Axel Hauschild, MD

Panel Discussion 1 – Stratifying the Risk for Progression in NMSC
All Faculty plus Patient Video Commentary

Panel Discussion 2 – Navigating Immunotherapy in Advanced CSCC
All Faculty plus Patient Video Commentary

Panel Discussion 3 – Assessing the Role of Immunotherapy in Advanced BCC
All Faculty plus Patient Video Commentary

Summary Remarks and Audience Q&A
All Faculty

“No pain no gain”: time to rethink and end the myth in AK treatment?
Room 2

Towards a successful patient engagement in AK: efficacy, tolerability and adherence trade-offs, and the use of tele-dermatology to optimize patient management
Prof. David Moreno Ramírez (Spain)

Apoptotic or necrotic cell death: how does this affect the treatment of AK?
Prof. Yolanda Gilaberte (Spain)

Learning from clinical experience in AK treatments and impact on patient profiles
Prof. Julia Welzel (Germany)

Q&A discussion
All faculty

Evolving Individualised Care Management Strategies for BRAF-Mutant Melanoma: A Case-Based Discussion
Room 1 (Main)

Welcome & Introductions
Professor Enrique Espinosa

Case 1: Adjuvant Therapy Differentiation: Patient Characteristics and Safety Profiles
Informing Treatment Selection

Case Introduction
Professor Christoph Höller

Panel Discussion and Audience Q&A
Professor Enrique Espinosa and Professor Christoph Höller

Case Outcome
Professor Christoph Höller

Case 2: Navigating Treatment Selection From the Adjuvant to First-Line Metastatic
Settings and Beyond
Case Introduction

Professor Enrique Espinosa
Panel Discussion and Audience Q&A

Professor Enrique Espinosa and Professor Christoph Höller
Case Outcome

Professor Enrique Espinosa

Conclusions
Professor Enrique Espinosa and Professor Christoph Höller